Dashboard
Manage Tickers

BCAB BioAtla, Inc.

Nasdaq bioatla.com


$ 0.75 $ 0.02 (2.33 %)    

Friday, 17-Oct-2025 11:02:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 600.21 $ 2.53 (0.42 %)
DIA $ 460.29 $ 0.93 (0.2 %)
SPY $ 661.06 $ 1.60 (0.24 %)
TLT $ 91.05 $ -0.18 (-0.2 %)
GLD $ 391.84 $ -5.35 (-1.35 %)
$ 0.7363
$ 0.76
$ 0.74 x 100
$ 0.75 x 631
$ 0.70 - $ 0.78
$ 0.24 - $ 2.53
1,439,637
na
43.24M
$ 2.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-24-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

bioatla-will-present-clinical-data-for-its-investigational-axl-targeting-antibody-drug-conjugate-mecbotamab-vedotin-at-the-sitc-2025-annual-meeting
BioAtla Will Present Clinical Data For Its...
10/03/2025 13:03:06

BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active B...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/16/2025 21:06:11

bioatla-highlights-fda-alignment-on-phase-3-ozuriftamab-vedotin-trial-design-says-co-continues-preparations-for-enabling-initiation-of-phase-3-study-co-maintains-previous-guidance
BioAtla Highlights FDA Alignment On Phase ...
09/08/2025 12:07:08

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential a...

jmp-securities-downgrades-bioatla-to-market-perform
JMP Securities Downgrades BioAtla to Marke...
08/13/2025 14:15:27

JMP Securities analyst Reni J. Benjamin downgrades BioAtla (NASDAQ:BCAB) from Market Outperform to Market Perform.

bioatla-q2-eps-032-misses-029-estimate
BioAtla Q2 EPS $(0.32) Misses $(0.29) Esti...
08/07/2025 20:09:38

BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by ...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

bioatla-to-present-first-in-human-phase-i-study-of-dual--cab-epcam-x-cd3-bispecific-t-cell-engager-ba3182-in-patients-with-treatment-refractory-metastatic-adenocarcinoma-at-esmo-tat-asia-meeting
BioAtla To Present First-In-Human Phase I ...
07/17/2025 12:52:33

bioatla-presented-data-from-ongoing-dose-escalation-of-ba3182-at-esmo-gastrointestinal-cancers-congress
BioAtla PResented Data From Ongoing Dose E...
07/03/2025 12:01:42

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
06/09/2025 21:06:01

reported-earlier-bioatla-reports-45-orr-and-100-dcr-in-heavily-pretreated-hpv-opscc-patients-in-phase-2-trial-of-ozuriftamab-vedotin
Reported Earlier: BioAtla Reports 45% ORR ...
06/02/2025 15:14:27

45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior l...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/21/2025 21:06:07

bioatla-q1-eps-026-beats-031-estimate
BioAtla Q1 EPS $(0.26) Beats $(0.31) Estimate
05/06/2025 20:16:25

BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16...

Core News & Articles
Earnings Scheduled For May 6, 2025
05/06/2025 08:32:41

a-preview-of-bioatlas-earnings
A Preview Of BioAtla's Earnings
05/05/2025 20:02:41

bioatlas-phase-2-trial-of-ozuriftamab-vedotin-selected-for-poster-presentation-at-2025-asco
BioAtla's Phase 2 Trial Of Ozuriftamab Ved...
04/23/2025 14:09:15

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focuse...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
04/14/2025 21:06:19

citizens-capital-markets-maintains-market-outperform-on-bioatla-lowers-price-target-to-1
Citizens Capital Markets Maintains Market ...
03/31/2025 14:33:46

Citizens Capital Markets analyst Reni Benjamin maintains BioAtla (NASDAQ:BCAB) with a Market Outperform and lowers the price...

hc-wainwright--co-reiterates-neutral-on-bioatlato-neutral
HC Wainwright & Co. Reiterates Neutral on ...
03/31/2025 10:50:17

HC Wainwright & Co. analyst Arthur He reiterates BioAtla (NASDAQ:BCAB) from Neutral to Neutral.

bioatla-is-extending-its-runway-beyond-key-clinical-readouts-in-1h-2026-by-restructuring-and-realigning-resources-which-includes-a-workforce-reduction-of-over-30
BioAtla Is Extending Its Runway Beyond Key...
03/27/2025 20:24:03

Corporate UpdatesBioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resour...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION